MX2020001404A - Dihidrooxadiazinonas. - Google Patents
Dihidrooxadiazinonas.Info
- Publication number
- MX2020001404A MX2020001404A MX2020001404A MX2020001404A MX2020001404A MX 2020001404 A MX2020001404 A MX 2020001404A MX 2020001404 A MX2020001404 A MX 2020001404A MX 2020001404 A MX2020001404 A MX 2020001404A MX 2020001404 A MX2020001404 A MX 2020001404A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- preparing
- pharmaceutical compositions
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención proporciona compuestos de dihidrooxidiazinona de la fórmula general (I): (ver Fórmula) en donde R1, R2, R3, y R4 son como se definen en el presente, procedimientos para la preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en especial de enfermedades hiperproliferativas, como un único agente o en combinación con otros ingredientes activos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762541627P | 2017-08-04 | 2017-08-04 | |
PCT/EP2018/071039 WO2019025562A1 (en) | 2017-08-04 | 2018-08-02 | DIHYDROOXADIAZINONES |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001404A true MX2020001404A (es) | 2020-03-12 |
Family
ID=63207725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001404A MX2020001404A (es) | 2017-08-04 | 2018-08-02 | Dihidrooxadiazinonas. |
Country Status (25)
Country | Link |
---|---|
US (3) | US11427553B2 (es) |
EP (1) | EP3661517B1 (es) |
JP (2) | JP2020529439A (es) |
KR (1) | KR20200036914A (es) |
CN (1) | CN111212647B (es) |
AR (1) | AR112402A1 (es) |
AU (1) | AU2018309356B2 (es) |
BR (1) | BR112020002351A2 (es) |
CA (1) | CA3071800A1 (es) |
CL (1) | CL2020000303A1 (es) |
CO (1) | CO2020001242A2 (es) |
CR (1) | CR20200057A (es) |
CU (1) | CU24608B1 (es) |
EA (1) | EA202090448A1 (es) |
EC (1) | ECSP20008441A (es) |
IL (1) | IL272098B2 (es) |
JO (1) | JOP20200024A1 (es) |
MA (1) | MA49750A (es) |
MX (1) | MX2020001404A (es) |
PH (1) | PH12020500134A1 (es) |
SG (1) | SG11201913775UA (es) |
TW (1) | TWI791581B (es) |
UA (1) | UA125731C2 (es) |
UY (1) | UY37832A (es) |
WO (1) | WO2019025562A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
CA3071795A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
WO2020157188A1 (en) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | Dihydrooxadiazinones for the treatment of hyperproliferative diseases |
EP4301371A1 (en) | 2021-03-03 | 2024-01-10 | Bayer Aktiengesellschaft | Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma |
EP4289828A1 (en) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Method for the preparation of a 3,6-dihydro-2h-1,3,4-oxadiazin-2-one |
EP4289829A1 (en) | 2022-06-10 | 2023-12-13 | Bayer Aktiengesellschaft | Crystalline forms of (6s)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazin-2-one |
WO2024109919A1 (zh) * | 2022-11-24 | 2024-05-30 | 盛睿泽华医药科技(苏州)有限公司 | 吡啶酮化合物及其制备方法和用途 |
CN118047833A (zh) * | 2024-01-31 | 2024-05-17 | 海南大学 | 含二茂铁的取代氨基乙酰胺类化合物及其制备方法和应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4097671A (en) * | 1975-08-28 | 1978-06-27 | General Electric Company | Dihydrooxadiazinones and method for making |
US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
US4258094A (en) * | 1979-04-26 | 1981-03-24 | Brunswick Corporation | Melt bonded fabrics and a method for their production |
US4334030A (en) | 1979-11-23 | 1982-06-08 | General Electric Company | Thermoplastic foamable blends |
EP0052442B1 (en) | 1980-11-14 | 1985-09-11 | Imperial Chemical Industries Plc | Heterocyclic compounds |
EP0059688B1 (de) | 1981-03-04 | 1985-05-15 | Ciba-Geigy Ag | Pyridazinone, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen und deren Verwendung |
US4495185A (en) | 1981-11-12 | 1985-01-22 | Imperial Chemical Industries, Plc | 1,2,4-Triazin-3(2H) ones |
ZA827641B (en) | 1981-11-12 | 1983-09-28 | Ici Plc | Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity |
US4581356A (en) | 1983-03-22 | 1986-04-08 | Fujisawa Pharmaceutical Co., Ltd. | Triazine derivatives, and pharmaceutical compositions comprising the same |
GB8310435D0 (en) | 1983-04-18 | 1983-05-25 | Fujisawa Pharmaceutical Co | Triazine derivatives |
JPS59196874A (ja) | 1983-04-22 | 1984-11-08 | Fujisawa Pharmaceut Co Ltd | トリアジン誘導体 |
JPS6153270A (ja) | 1984-08-17 | 1986-03-17 | チバ・ガイギー・アクチエンゲゼルシヤフト | 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤 |
US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
GB8426804D0 (en) | 1984-10-23 | 1984-11-28 | Ciba Geigy Ag | Pyridazinones preparations |
ES2031821T3 (es) | 1985-10-17 | 1993-01-01 | Smith Kline & French Laboratories Limited | Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo. |
EP0303418A3 (en) | 1987-08-11 | 1990-11-07 | Smithkline Beecham Laboratoires Pharmaceutiques | Substituted indolones, useful in the treatment of heart or asthmatic diseases |
ATE180475T1 (de) | 1990-09-21 | 1999-06-15 | Rohm & Haas | Dihydropyridazinone und pyridazinone als fungizide |
JPH0676325B2 (ja) * | 1992-05-08 | 1994-09-28 | 三井東圧化学株式会社 | オキサジアジン誘導体を有効成分として含有する抗血栓剤 |
ATE209189T1 (de) | 1992-07-01 | 2001-12-15 | Ortho Pharma Corp | 1-arylsulfonyl-3-phenyl-1,4,5,6- tetrahydropyridazinen |
JPH07291968A (ja) | 1994-04-26 | 1995-11-07 | Mitsubishi Chem Corp | トリアジノン誘導体またはその塩類 |
DE19929787A1 (de) * | 1999-06-29 | 2001-01-04 | Bayer Ag | Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung |
KR20040012720A (ko) * | 2001-02-12 | 2004-02-11 | 메르크 파텐트 게엠베하 | 심근 질환에서 제 4형 포스포디에스테라제 저해제의 용도 |
WO2008108602A1 (en) | 2007-03-07 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
CN101538245B (zh) | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
US9212146B2 (en) | 2008-03-18 | 2015-12-15 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted pyridazinones for the treatment of tumors |
CA2758774C (en) | 2009-04-15 | 2015-02-03 | Research Triangle Institute | Monoamine reuptake inhibitors |
FR2948940B1 (fr) * | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP2566864B1 (en) | 2010-05-07 | 2014-09-03 | Boehringer Ingelheim International GmbH | Pyridazinones as gpr119 agonists |
EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
US9890127B2 (en) | 2013-03-11 | 2018-02-13 | The Broad Institute, Inc. | Compounds and compositions for the treatment of cancer |
TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
US11207320B2 (en) | 2015-08-13 | 2021-12-28 | The Broad Institute, Inc. | Compositions and methods for cancer expressing PDE3A or SLFN12 |
WO2017121684A1 (en) | 2016-01-14 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
CA3234176A1 (en) | 2016-02-05 | 2017-08-10 | Antje Margret Wengner | Compounds, compositions and methods for cancer patient stratification and cancer treatment |
KR101831772B1 (ko) * | 2016-03-24 | 2018-03-06 | 아이디에스(주) | 복합 광원 모듈을 가지는 카메라 접사용 기구 및 이를 이용한 지문 시편 촬영 방법 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
CA3071795A1 (en) | 2017-08-04 | 2019-02-07 | Bayer Aktiengesellschaft | 6-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
TW202031677A (zh) | 2018-11-01 | 2020-09-01 | 美商博得學院股份有限公司 | Pde3調節劑反應性癌症之鑑定 |
AR117929A1 (es) | 2019-02-01 | 2021-09-01 | Bayer Ag | Compuestos de 1,2,4-triazin-3(2h)-ona |
-
2018
- 2018-08-01 JO JOP/2020/0024A patent/JOP20200024A1/ar unknown
- 2018-08-02 BR BR112020002351-5A patent/BR112020002351A2/pt unknown
- 2018-08-02 KR KR1020207005998A patent/KR20200036914A/ko unknown
- 2018-08-02 CN CN201880050751.0A patent/CN111212647B/zh active Active
- 2018-08-02 CR CR20200057A patent/CR20200057A/es unknown
- 2018-08-02 UA UAA202001558A patent/UA125731C2/uk unknown
- 2018-08-02 JP JP2020505898A patent/JP2020529439A/ja active Pending
- 2018-08-02 WO PCT/EP2018/071039 patent/WO2019025562A1/en unknown
- 2018-08-02 US US16/635,504 patent/US11427553B2/en active Active
- 2018-08-02 MX MX2020001404A patent/MX2020001404A/es unknown
- 2018-08-02 SG SG11201913775UA patent/SG11201913775UA/en unknown
- 2018-08-02 EP EP18755153.6A patent/EP3661517B1/en active Active
- 2018-08-02 CU CU2020000008A patent/CU24608B1/es unknown
- 2018-08-02 AU AU2018309356A patent/AU2018309356B2/en not_active Ceased
- 2018-08-02 CA CA3071800A patent/CA3071800A1/en active Pending
- 2018-08-02 EA EA202090448A patent/EA202090448A1/ru unknown
- 2018-08-02 MA MA049750A patent/MA49750A/fr unknown
- 2018-08-03 TW TW107127172A patent/TWI791581B/zh active
- 2018-08-03 AR ARP180102218 patent/AR112402A1/es unknown
- 2018-08-03 UY UY0001037832A patent/UY37832A/es not_active Application Discontinuation
-
2020
- 2020-01-16 IL IL272098A patent/IL272098B2/en unknown
- 2020-01-17 PH PH12020500134A patent/PH12020500134A1/en unknown
- 2020-02-04 EC ECSENADI20208441A patent/ECSP20008441A/es unknown
- 2020-02-04 CL CL2020000303A patent/CL2020000303A1/es unknown
- 2020-02-04 CO CONC2020/0001242A patent/CO2020001242A2/es unknown
-
2022
- 2022-07-11 US US17/862,255 patent/US20230017200A1/en active Pending
- 2022-07-14 US US17/865,236 patent/US11773070B2/en active Active
-
2023
- 2023-06-13 JP JP2023097166A patent/JP2023115065A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
PH12021550792A1 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
MX2020001404A (es) | Dihidrooxadiazinonas. | |
PH12018550173A1 (en) | Pyrazolopyrimidine derivatives | |
MX2020001403A (es) | Nuevos derivados de quinolina. | |
PH12019501846A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
CR20210201A (es) | Nuevos compuestos antihelmínticos | |
PH12019502851A1 (en) | New azaquinoline derivatives | |
CR20220236A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
WO2020126968A3 (en) | Urea derivatives for use against proliferative diseases | |
MX2019012803A (es) | Nuevos derivados de pirazol biciclicos. | |
MX2020011873A (es) | Nuevos derivados de quinolina. | |
WO2017198341A8 (en) | MACROCYCLIC INDOLE DERIVATIVES | |
PH12017501133A1 (en) | Pyrazolopyridinamines | |
WO2015150449A3 (en) | Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2 | |
PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
PH12019500808A1 (en) | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof |